Li Ting, Zhou Jianying, Wang Qing
Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China.
Zhongguo Fei Ai Za Zhi. 2022 Apr 20;25(4):272-277. doi: 10.3779/j.issn.1009-3419.2022.101.14. Epub 2022 Mar 28.
In recent years, with the widespread use of immunodepressant agents, Pneumocystis jirovecii pneumonia (PJP) has been significantly found in non-human immunodeficiency virus (HIV) patients, such as those with malignancies, post-transplantation and autoimmune diseases. Although the risk factors and management of PJP have been extensively studied in the hematologic tumor and post-transplant populations, the research on real tumor cases is insufficient. Lung cancer has been the most common tumor with the highest number of incidence and death worldwide, and the prognosis of lung cancer patients infected with PJP is poor in clinical practice. By reviewing the previous studies, this paper summarized the epidemiology and clinical manifestations of PJP in lung cancer patients, the risk factors and possible mechanisms of PJP infection in lung cancer patients, diagnosis and prevention, and other research progresses to provide reference for clinical application. .
近年来，随着免疫抑制剂的广泛使用，在非人类免疫缺陷病毒（HIV）患者中，如患有恶性肿瘤、移植后及自身免疫性疾病的患者中，显著发现了耶氏肺孢子菌肺炎（PJP）。尽管PJP的危险因素及管理在血液系统肿瘤和移植后人群中已得到广泛研究，但对实体肿瘤病例的研究仍不足。肺癌一直是全球发病率和死亡率最高的最常见肿瘤，在临床实践中，感染PJP的肺癌患者预后较差。通过回顾既往研究，本文总结了肺癌患者中PJP的流行病学、临床表现、肺癌患者PJP感染的危险因素及可能机制、诊断与预防等研究进展，为临床应用提供参考。
